Heavy Metal Containing Doai Patents (Class 514/492)
  • Patent number: 10683316
    Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 16, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Trustees of Boston University
    Inventors: John C. Kash, Jeffery K. Taubenberger, Rodney L. Levine, Susan Doctrow
  • Patent number: 10596191
    Abstract: A DDS preparation of a platinum complex, which selectively releases a highly active platinum complex in cells that are under reducing conditions, and exhibits high antitumor activity that is required from a medicine, is still not available, and there is a demand for a novel DDS preparation of a platinum complex that may be used in clinical fields. There is provided a polymer conjugate of a hexa-coordinated platinum complex, the polymer conjugate comprising a block copolymer having a polyethylene glycol structural moiety and a polyaspartic acid moiety or a polyglutamic acid moiety; and a hexa-coordinated platinum complex having a halogen atom and a hydroxyl group at the axial positions, the hexa-coordinated platinum complex being bonded, directly or via a spacer, to a side-chain carboxyl group of the block copolymer.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 24, 2020
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaharu Nakamura, Tsuyoshi Fukuda, Yusaku Kikuchi, Chihiro Watanabe
  • Patent number: 10385083
    Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 20, 2019
    Assignee: Ohio University
    Inventor: Rathindra N. Bose
  • Patent number: 10327423
    Abstract: A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center selected from amino acids or ?-hydroxy acids, o-hydroxy benzoic acids or pyridine-2-carboxylic acids, such as ferric quinate, ferric tyrosine, ferric DOPA and ferric phenylalanine. Compounds which are structural and/or functional variants, derivatives and/or analogs of the foregoing compounds, as further described herein are also disclosed.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: June 25, 2019
    Assignee: Akeso Biomedical, Inc.
    Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
  • Patent number: 10238689
    Abstract: The present disclosure provides a method for killing persister cells with mitomycin C and/or cisplatin, or derivatives thereof. Recalcitrant infections are difficult to treat due to persister cells, a subpopulation of all bacterial populations that is highly tolerant against all traditional antibiotics since the cells are dormant and antibiotics are designed to kill growing cells. Here, we show that MMC and cisplatin eradicate persister cells through a growth-independent mechanism, cross-linking DNA. We find both agents are effective against both planktonic cultures and highly robust biofilm cultures for a broad range of bacterial species, including commensal Escherichia coli K-12 as well as pathogenic species of E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In certain approaches cisplatin is superior to MMC.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 26, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Thomas Wood, Brian Kwan, Nityananda Chowdhury
  • Patent number: 10183027
    Abstract: The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin ?v?3.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 22, 2019
    Assignee: Hong Kong Baptist University
    Inventors: Ka Leung Wong, Hongguang Li
  • Patent number: 10012659
    Abstract: Methods for diagnosing or assisting in the diagnosis of iron-related pathologies are provided. The methods are based on the correlation of the degree of iron-specific hypercoagulability with clinical disease. One embodiment provides a method for diagnosing or assisting in diagnosing a subject having or suspected of having an iron-related pathology by analyzing a blood sample obtained from the subject to obtain viscoelastic parameters of the blood sample as the blood sample coagulates. A variation in the viscoelastic parameters of the blood sample relative to a blood sample from a healthy subject indicates the subject has or will likely develop an iron-related pathology. Subjects having an iron-related pathology have viscoelastic parameters that are indicative of enhanced coagulation and/or diminished fibrinolysis compared to the viscoelastic parameters of the blood sample from the healthy subject.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: July 3, 2018
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventor: Vance G. Nielsen
  • Patent number: 9991543
    Abstract: Provided are compositions having the formula MnTi(L1)(L2)(L3) wherein L1 is a catecholate, and L2 and L3 are each independently selected from catecholates, ascorbate, citrate, glycolates, a polyol, gluconate, glycinate, hydroxyalkanoates, acetate, formate, benzoates, malate, maleate, phthalates, sarcosinate, salicylate, oxalate, a urea, polyamine, aminophenolates, acetylacetone or lactate; each M is independently Na, Li, or K; n is 0 or an integer from 1-6. Also provided are energy storage systems.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: June 5, 2018
    Assignee: Lockheed Martin Advanced Energy Storage, LLC
    Inventors: Arthur J. Esswein, Steven Y. Reece, Evan R. King, John Goeltz, Desiree D. Amadeo
  • Patent number: 9961886
    Abstract: A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center selected from amino acids or ?-hydroxy acids, o-hydroxy benzoic acids or pyridine-2-carboxylic acids, such as ferric quinate, ferric tyrosine, ferric DOPA and ferric phenylalanine. Compounds which are structural and/or functional variants, derivatives and/or analogs of the foregoing compounds, as further described herein are also disclosed.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: May 8, 2018
    Assignee: Akeso Biomedical, Inc.
    Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
  • Patent number: 9744236
    Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: August 29, 2017
    Assignees: The Trustees of Columbia University in the City of New York, Universidad de Buenos Aires
    Inventors: Rafael Yuste, Roberto Etchenique, Luis Baraldo
  • Patent number: 9688709
    Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: June 27, 2017
    Assignee: OHIO UNIVERSITY
    Inventor: Rathindra N. Bose
  • Patent number: 9675569
    Abstract: The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-?, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: June 13, 2017
    Inventor: Alain Martin
  • Patent number: 9649426
    Abstract: A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-? inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: May 16, 2017
    Assignee: PROPHY MED AB
    Inventors: Lars Bruce, Staale Petter Lyngstadaas
  • Patent number: 9603940
    Abstract: A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: March 28, 2017
    Assignees: IHI Corporation
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi, Hiroshi Sato
  • Patent number: 9504252
    Abstract: The compositions and methods for control of microbial growth, for example, in oil and gas field fluids. The present invention also relates to microbicides, and more particularly, to the use of biocides in gas and oil field fluids.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: November 29, 2016
    Assignee: BUCKMAN LABORATORIES INTERNATIONAL, INC.
    Inventors: Theodore S. Sumrall, Thomas E. McNeel
  • Patent number: 9410954
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: August 9, 2016
    Assignees: FOUNDATION MEDICINE, INC., UCL Business PLC
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Patent number: 9175024
    Abstract: Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: November 3, 2015
    Assignee: BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Xiaoping Chen, Zejun Gao, Xiaoping Meng, Shouming Wen, Yashi Yan, Feng Zhao
  • Patent number: 9132115
    Abstract: The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: September 15, 2015
    Inventor: Heidi Kay
  • Publication number: 20150148301
    Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
  • Publication number: 20150148413
    Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: Mordechai Chevion, Vladimir Vinokur, Eduard Berenshtein, Ron Eliashar, Baruch Bulvik
  • Publication number: 20150148292
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto.
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Scott D Boden, Sreedhara Sangadala
  • Publication number: 20150140124
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 21, 2015
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Publication number: 20150140122
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 21, 2015
    Applicant: INSERM (Institut National de la Sante et de la Rec herche)
    Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova
  • Publication number: 20150141342
    Abstract: The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Murray Korc, A. Jesse Gore, Gregory A. Cote, Stuart Sherman
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
  • Publication number: 20150118173
    Abstract: The invention relates to a formulation comprising caprylic acid ethanolamide and/or capric acid ethanolamide in combination with an aluminium salt and to its use.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 30, 2015
    Applicant: EVONIK INDUSTRIES AG
    Inventors: Mike Farwick, Oliver Springer, Matthias Mentel, Stefan Bergfried
  • Patent number: 9018199
    Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: April 28, 2015
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Paul Joseph Dyson, Wee Han Ang
  • Publication number: 20150110897
    Abstract: This disclosure provides a method for determining if a patient is likely to, or not likely to, experience ovarian cancer utilizing SP17 as a biomarker. It also provides methods and therapies to treat patients identified as at risk for ovarian cancer or alternatively, as identified as having a poorer prognosis.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 23, 2015
    Applicants: University of Southern California, Texas Tech University System
    Inventors: Wijbe Martin Kast, Maurizio Chiriva-Internati
  • Patent number: 9012483
    Abstract: The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered as a single oral dose comprised from 0.2-20 g.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: April 21, 2015
    Assignee: Bracco Imaging S.p.A.
    Inventors: Baranyai Zsolt, Ernö Brücher, Simona Bussi, Alessandro Maiocchi, Fulvio Uggeri
  • Patent number: 9012362
    Abstract: The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: April 21, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Thomas Seitz, Ulrike Wachendorff-Neumann, Peter Dahmen
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Publication number: 20150099804
    Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 9, 2015
    Inventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Eric Breitbart, Joseph Benevenia
  • Patent number: 9000036
    Abstract: Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: April 7, 2015
    Inventor: Baofa Yu
  • Publication number: 20150094276
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventor: Roger D. Tung
  • Patent number: 8986741
    Abstract: A sunscreen composition for application for plants comprises Titanium Dioxide (TiO2), Zinc Oxide (ZnO), Silicon Dioxide (SiO2), a surfactant, wetting agent, dispersant (SWD) and water. The composition forms a suspension concentrate when combined that when diluted in water provides a solution that provides uniform coverage using convention spraying equipment. A method of protecting plants including turfgrass from ultraviolet radiation, heat stress and/or sunburn comprises combining TiO2, ZnO, SiO2, SWD and water to form a suspension concentrate. The suspension concentrate is then diluted in water and applied to an area in which sun protection is desired.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: March 24, 2015
    Inventor: Scott May
  • Patent number: 8987491
    Abstract: The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R? is a phenyl group or a group of general Formula —(CH2)q—COOH wherein q=1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: March 24, 2015
    Assignees: Societe de Coordination de Recherches Therapeutiques, Universite Paris-Sud 11, Centre National de la Recherche Scientifique
    Inventors: Philippe Collery, Jean D'Angelo, Georges Morgant
  • Publication number: 20150071919
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Thomas F. WHITE, Dan HOTH
  • Patent number: 8975294
    Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: March 10, 2015
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Mordechai Chevion, Vladimir Vinokur, Eduard Berenshtein, Ron Eliashar, Baruch Bulvik
  • Publication number: 20150064114
    Abstract: A liposome comprising a lipid bilayer, a hydrophobic active ingredient, and an imaging agent, a pharmaceutical composition including the liposome, and a method of delivering an active ingredient to a target site in the body of a subject using the liposome.
    Type: Application
    Filed: June 11, 2014
    Publication date: March 5, 2015
    Inventors: Sun Min PARK, Kitae PARK, Hyun Ryoung KIM, Eun Sung PARK
  • Patent number: 8968791
    Abstract: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 3, 2015
    Assignee: Novus International, Inc.
    Inventors: Jeremy D. Moore, Thomas R. Hampton, Robert Harrell
  • Publication number: 20150057237
    Abstract: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 26, 2015
    Applicant: SupraPolix B.V.
    Inventors: Patricia Yvonne Wilhelmina DANKERS, Gaby Maria Leonarda HOORNE-VAN GEMERT, Henricus Marie JANSSEN, Egbert Willem MEIJER, Anton Willem BOSMAN
  • Publication number: 20150056300
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 26, 2015
    Applicant: BIND Therapeutics, Inc.
    Inventors: David Dewitt, Maria Figueiredo, Hong Wang, Greg Troiano, Young-Ho Song
  • Publication number: 20150050360
    Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.
    Type: Application
    Filed: June 28, 2012
    Publication date: February 19, 2015
    Applicants: Singapore Health Services Pte Ltd., National University of Singapore
    Inventors: Patrick Tan, Tatiana Ivanova
  • Publication number: 20150045428
    Abstract: The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, which in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O?Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.
    Type: Application
    Filed: January 3, 2013
    Publication date: February 12, 2015
    Inventors: Shiladitya Sengupta, Sazid Hussain, Dipankar Pramanik, Monideepa Roy, Seikh Samad Hossain
  • Patent number: 8952057
    Abstract: Compositions containing polymetal complexes are useful in treating anorectal disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: JR Chem, LLC
    Inventor: José E. Ramirez
  • Publication number: 20150037437
    Abstract: A chemotherapy agent or a pharmaceutical composition including chemotherapy agent and artificial cerebrospinal fluid, wherein the chemotherapy agent at a concentration of between 0.01 mg/ml and 0.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 5, 2015
    Applicant: RENISHAW PLC
    Inventors: Steven Streatfield Gill, Edward White
  • Publication number: 20150030653
    Abstract: A method for repairing an injury of cartilage in a patient by local administration of an organovanadium agent or use of an implantable device for delivery of an organovanadium agent. Implantable devices containing an organovanadium agent and methods of making these implantable devices are also disclosed.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 29, 2015
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Aaron Wey, Joseph Benevenia, Virak Tan
  • Publication number: 20150030587
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 29, 2015
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Patent number: RE45471
    Abstract: A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride. In the formulae I and II, R1, A, R2, R3, m and n are as defined in the description.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: April 14, 2015
    Assignee: Nanocarrier Co., Ltd.
    Inventors: Mitsunori Harada, Iulian Bobe, Takashi Shimizu